Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding: 2019-2021

Historic Shares Outstanding for Lyell Immunopharma (LYEL) over the last 1 years, with Dec 2021 value amounting to $242.7 million.

  • Lyell Immunopharma's Shares Outstanding rose 1459.01% to $242.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $242.7 million, marking a year-over-year increase of 1459.01%. This contributed to the annual value of $242.7 million for FY2021, which is 1459.01% up from last year.
  • Lyell Immunopharma's Shares Outstanding amounted to $242.7 million in Q4 2021, which was up 1.23% from $239.8 million recorded in Q3 2021.
  • In the past 5 years, Lyell Immunopharma's Shares Outstanding registered a high of $242.7 million during Q4 2021, and its lowest value of $11.2 million during Q4 2019.
  • Its 3-year average for Shares Outstanding is $149.6 million, with a median of $238.5 million in 2021.
  • Data for Lyell Immunopharma's Shares Outstanding shows a peak YoY skyrocketed of 1,459.01% (in 2021) over the last 5 years.
  • Lyell Immunopharma's Shares Outstanding (Quarterly) stood at $11.2 million in 2019, then soared by 39.25% to $15.6 million in 2020, then skyrocketed by 1,459.01% to $242.7 million in 2021.
  • Its last three reported values are $242.7 million in Q4 2021, $239.8 million for Q3 2021, and $238.5 million during Q2 2021.